Medical Developments International | MVP

Stock Price
0.57
Daily Change
-0.01 -0.87%
Monthly
-19.72%
Yearly
35.71%
Q3 Forecast
0.57

Peers Price Chg Day Year Date
Avita Medical 1.35 0.01 0.37% -48.86% Sep/08
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Clinuvel Pharmaceuticals 10.94 -0.34 -3.01% -24.81% Sep/08
Genetic Signatures 0.27 -0.01 -3.57% -62.76% Sep/08
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Medical Developments International 0.57 -0.01 -0.87% 35.71% Sep/08
Neuren Pharmaceuticals 20.80 0.32 1.56% 51.27% Sep/08
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Paradigm Biopharmaceuticals 0.28 -0.01 -1.79% 17.02% Sep/08
PYC Therapeutics 1.26 0.01 0.80% 5.00% Sep/08
Starpharma Holdings 0.14 0.01 3.85% 42.11% Sep/08
Telix Pharmaceuticals 13.60 -0.20 -1.45% -22.51% Sep/08
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05


Medical Developments International Ltd traded at 0.57 this Monday September 8th, decreasing 0.01 or 0.87 percent since the previous trading session. Looking back, over the last four weeks, Medical Developments International lost 19.72 percent. Over the last 12 months, its price rose by 35.71 percent. Looking ahead, we forecast Medical Developments International Ltd to be priced at 0.57 by the end of this quarter and at 0.56 in one year, according to Trading Economics global macro models projections and analysts expectations.

Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.